10th Sep 2018 11:52
LONDON (Alliance News) - Sareum Holdings PLC said Monday it will develop SDC-1801 as a possible treatment for autoimmune diseases.
The molecule, SDC-1801, has been formally selected for advancement through pre-clinical development. SDC-1801 is intended to reduce the body's inflammatory response in autoimmune diseases such as rheumatoid arthritis and lupus.
The drug developer said that SDC-1801 shows "potential for once-daily oral dosing" and has a "good early safety profile", noting that similar molecules have already shown promise in lupus and inflammatory bowel disease.
"With SDC-1801, we believe we are entering this space with a strong candidate that exhibits potentially best-in-class features. We intend to focus our resources on advancing SDC-1801 through preclinical development and into clinical trials over the next 18 months. At the same time, we will continue our discussions with potential licence partners for this exciting drug candidate," said Sarem Chief Executive Tim Mitchell.
Shares in Sareum were up 0.8% at 0.78 pence on Monday.
Related Shares:
Sareum